Eli Lilly and Co. plans to buy Centessa Pharmaceuticals plc for $6.3 billion in up-front cash and another potential $1.5 billion through contingent value rights, gaining access to a pipeline of orexin ...

Eli Lilly and Co. is deepening its investment in artificial intelligence-driven drug discovery through a multibillion-dollar expansion of its collaboration with Hong-Kong listed Insilico Medicine Inc.

Braveheart Bio Inc. reported positive results from an open-label randomized phase II dose-ranging study of BHB-1893 (HRS-1893) in obstructive hypertrophic cardiomyopathy. Results presented at the ...

Certain cancers, such as triple-negative breast cancer, produce antibodies that, although they help fight the tumor, can cross the blood-brain barrier and alter the function of NMDA receptors (NMDAR) ...

Analysts were sounding pleased and the company intends to go ahead with a regulatory filing, but investors seem to have wanted more from Viridian Therapeutics Inc.’s top-line data from the elegrobart ...

Parkinson’s disease is a progressive neurodegenerative disorder best known for its motor symptoms. However, a proportion of patients also develop dementia as the condition advances. Yet the biological ...

*For more details about COVID-19 therapeutics and vaccines, diagnostic products and clinical trial delays, go to BioWorld Snapshots.

After capturing the North American market with Wegovy (semaglutide) and Zepbound (tirzepatide), Novo Nordisk A/S and Eli Lilly and Co. are advancing blockbuster glucagon-like peptide-1 (GLP-1) ...

In a win for the rare disease space, the U.S. FDA granted accelerated approval for Rocket Pharmaceuticals Inc.’s Kresladi ...

IKZF1-4 are transcription factors that regulate cellular differentiation, proliferation and survival. At the American Chemical Society (ACS) Spring 2026 meeting this week in Atlanta, Bristol Myers ...

Onkure Therapeutics Inc. has announced an oversubscribed $150 million private placement which the company intends to use to fund the preclinical and clinical development of its next-generation PI3Kα ...

Year-to-date money raised in public, private and other financings of biopharma companies. Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing Cookie Settings ...